AlF-OC

Phase 2Small molecule

UUniversitaire Ziekenhuizen KU Leuven

AlF-OC is one of 7 small molecule programs targeting Carotid Artery Disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Carotid Artery DiseaseActive, not recruiting

Carotid Artery DiseasePhase 2

Active, not recruiting

Competition

Competitive Landscape

9 competitors in Carotid Artery Disease

#DrugCompanyPhaseTrials

Lithobid

SSolvay Pharmaceuticals

Optison

1 3

Bayer Aspirin

Plavix

Zocor

AlF-OC

UUniversitaire Ziekenhuizen KU Leuven

Phase 2

1 7

DPA-714

UUniversity of Alabama at Birmingham

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2029

Phase 2Recruiting

Carotid Artery Disease

NCT07104487

Clinical

Trials by Indication[1]

Carotid Artery Disease1 trial

[18F]AlF-NOTA-octreotide PET/MRI in Carotid Artery Disease

Recruiting·UUniversitaire Ziekenhuizen KU Leuven·Phase 2·NCT07104487·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for AlF-OC. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AlF-OC compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AlF-OC. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Universitaire Ziekenhuizen KU Leuven company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UUniversitaire Ziekenhuizen KU Leuven

AlF-OC

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2029

Trials by Indication[1]

Carotid Artery Disease1 trial

References

Drug Info

Quick Facts

Related News